University of Maryland, Baltimore
umaryland.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
687
Active
167
Phase 3
21
Total enrollment
702,231
Pipeline matrix
Showing 40 of 84 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vivotif Typhoid Oral Vaccine | — | — | — | — | — | 3 | |
| Varenicline | — | — | — | 4 | |||
| Vaxchora | — | — | — | — | — | 2 | |
| Mineral Trioxide Aggregate | — | — | — | — | — | 1 | |
| Biodentin | — | — | — | — | — | 1 | |
| Isocapnic Oxygen | — | — | — | — | — | 1 | |
| Iodinated Contrast Agent | — | — | — | — | — | 1 | |
| Azithromycin to pregnant women | — | — | — | — | — | 1 | |
| Azithromycin to infants | — | — | — | — | — | 1 | |
| IL-23 | — | — | — | — | — | 1 | |
| Zinc Gluconate 30 MG | — | — | — | — | — | 1 | |
| Ceftriaxone 1 gram daily | — | — | — | — | — | 1 | |
| Ceftriaxone 2 grams daily | — | — | — | — | — | 1 | |
| Live Attenuated Influenza Vaccine | — | — | — | — | — | 1 | |
| Rocklatan | — | — | — | — | — | 1 | |
| Latanoprost | — | — | — | — | — | 1 | |
| Local anesthesia injections | — | — | — | — | — | 1 | |
| Vi-Typhoid Conjugate Vaccine | — | — | — | — | 2 | ||
| Vancomycin | — | — | — | — | — | 1 | |
| Antibiotic Cement Bead Pouch | — | — | — | — | — | 1 | |
| Meningococcal A Conjugate Vaccine | — | — | — | — | — | 1 | |
| Methadone | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | 5 | ||
| Hyperpolarized 13C-Pyruvate | — | — | — | — | 4 | ||
| Lofexidine | — | — | — | — | — | 2 | |
| Naloxone | — | — | — | — | — | 2 | |
| Neuromuscular Blocking Agents | — | — | — | — | — | 2 | |
| Arginine vasopressin | — | — | — | — | — | 1 | |
| Buspirone | — | — | — | — | — | 1 | |
| TSCV | — | — | — | — | — | 1 | |
| Typbar-TCV | — | — | — | — | — | 1 | |
| Treatment with Ketamine | — | — | — | — | — | 1 | |
| Treatment with Very Low Dose Ketamine | — | — | — | — | — | 1 | |
| niraparib/abiraterone acetate | — | — | — | — | — | 1 | |
| Androgen deprivation therapy | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Imdusiran | — | — | — | — | — | 1 | |
| Ankle robot training group | — | — | — | — | — | 1 | |
| Ankle robot training and functional electrical stimulation(FES) group | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 |
44 more active programs hidden
Next readouts
- 2023-09-25
- 2024-09-01
- 2025-01-30
- 2025-03-01
- 2025-12-30
- 2026-03
- 2026-04
- 2026-05
- 2026-05-31
- 2026-07
Top conditions
- Schizophrenia57
- Schizoaffective Disorder16
- Prostate Cancer13
- Breast Cancer12
- HIV12
- Hypertension10
- Traumatic Brain Injury10
- Opioid Use Disorder10
Frequently asked questions about University of Maryland, Baltimore
- How many clinical trials does University of Maryland, Baltimore have on ClinicalTrials.gov?
- University of Maryland, Baltimore is listed as the lead sponsor on 687 clinical trials in ClinicalTrials.gov, 167 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Maryland, Baltimore's trials are in Phase 3?
- 21 of University of Maryland, Baltimore's trials are in Phase 3, spread across 84 active drug programs.
- What therapeutic areas does University of Maryland, Baltimore focus on?
- University of Maryland, Baltimore's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Schizoaffective Disorder, Prostate Cancer, Breast Cancer, HIV.
- When are University of Maryland, Baltimore's next clinical trial readouts?
- University of Maryland, Baltimore has 10 upcoming primary-completion readouts tracked here; the soonest is “Genetics of Response to Canagliflozin”, expected around 2023-09-25.